
Researchers Unveil Universal Nasal Spray Vaccine Targeting Viruses, Bacteria, and Allergens
Stanford Medicine researchers have developed a nasal spray vaccine that activates the lungs’ innate immune system to provide months-long protection against a broad range of respiratory threats—including SARS-CoV-2, other coronaviruses, bacterial pneumonia pathogens, and even house dust mite allergens—in mice. If safety and efficacy are shown in humans, the approach could reduce the need for multiple yearly vaccines and idea of rapid protection during outbreaks, with Phase I trials moving forward and an estimated 5–7 years before potential availability.








